How far have we explored fungi to fight cancer?

CW How, YS Ong, SS Low, A Pandey, PL Show… - Seminars in cancer …, 2022 - Elsevier
The use of fungal cultures have been well documented in human history. Although its used
in healthcare, like penicillin and statins, have saved countless of lives, but there is still no …

Regulation of PD-L1 expression on cancer cells with ROS-modulating drugs

C Bailly - Life Sciences, 2020 - Elsevier
Monoclonal antibodies targeting the programmed-death 1 (PD-1) immune checkpoint or its
ligand PD-L1 have significantly improved the treatment of cancers but more efficient drugs …

[HTML][HTML] Downregulation of LncRNA-XIST inhibited development of non-small cell lung cancer by activating miR-335/SOD2/ROS signal pathway mediated pyroptotic …

J Liu, L Yao, M Zhang, J Jiang, M Yang… - Aging (albany NY), 2019 - ncbi.nlm.nih.gov
LncRNA-XIST participated in the regulation of Non-small cell lung cancer (NSCLC)
progression, but the underlying mechanisms are still unclear. This study showed that …

Therapeutic potential of SphK1 inhibitors based on abnormal expression of SphK1 in inflammatory immune related-diseases

Y Bu, H Wu, R Deng, Y Wang - Frontiers in Pharmacology, 2021 - frontiersin.org
Sphingosine kinase 1 (SphK1) a key enzyme that catalyzes the conversion of sphingosine
(Sph) to sphingosine 1-phosphate (S1P), so as to maintain the dynamic balance of …

Targeting the sphingosine kinase/sphingosine-1-phosphate signaling axis in drug discovery for cancer therapy

P Gupta, A Taiyab, A Hussain, MF Alajmi, A Islam… - Cancers, 2021 - mdpi.com
Simple Summary Cancer is the prime cause of death globally. The altered stimulation of
signaling pathways controlled by human kinases has often been observed in various human …

Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation

Y Guo, X Gan, H Zhou, H Zhou, S Pu, X Long, C Ren… - Life Sciences, 2020 - Elsevier
Depression is a common aspect of the modern lifestyle, and most patients are recalcitrant to
the current antidepressants. Fingolimod (FTY720), a sphingosine analogue approved for the …

The emerging roles of sphingosine 1-phosphate and SphK1 in cancer resistance: a promising therapeutic target

SS Alkafaas, MI Elsalahaty, DF Ismail… - Cancer Cell …, 2024 - Springer
Cancer chemoresistance is a problematic dilemma that significantly restrains numerous
cancer management protocols. It can promote cancer recurrence, spreading of cancer, and …

FTY720 nanoformulation induces O-GlcNacylation of synuclein to alleviate synucleinopathy

MN Sardoiwala, M Boddu, L Biswal… - ACS Chemical …, 2023 - ACS Publications
The post-translational modification and aggregation of alpha-synuclein are one of the major
causes of Parkinson's disease (PD) regulation. In that, the phosphorylation and nitration of …

Sphingosine‐1‐phosphate in mitochondrial function and metabolic diseases

M Duan, P Gao, S Chen, P Novák, K Yin… - Obesity …, 2022 - Wiley Online Library
Summary Sphingosine‐1‐phosphate (S1P) is a bioactive sphingolipid metabolite. The past
decade has witnessed exponential growth in the field of S1P research, partly attributed to …

Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo

MN Sardoiwala, S Karmakar, SR Choudhury - Carbohydrate Polymers, 2021 - Elsevier
Parkinson's disease (PD) develops due to oxidative stress, mitochondrial aberrations,
posttranslational modification, and α-Synuclein (α-Syn) aggregation. The α-synucleinopathy …